PMID- 35871241
OWN - NLM
STAT- MEDLINE
DCOM- 20220920
LR  - 20220920
IS  - 1432-1041 (Electronic)
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 78
IP  - 10
DP  - 2022 Oct
TI  - Tinzaparin-a review of its molecular profile, pharmacology, special properties, 
      and clinical uses.
PG  - 1555-1565
LID - 10.1007/s00228-022-03365-4 [doi]
AB  - PURPOSE: Low molecular weight heparins (LMWHs) are a group of heterogenous 
      moieties, long used in the prevention and treatment of thrombosis. They derive 
      from heparin and since they are prepared by different methods of 
      depolymerization, they differ in pharmacokinetic properties and anticoagulant 
      profiles, and thus are not clinically interchangeable. METHODS: In this review we 
      provide an overview of tinzaparin's main characteristics and uses. RESULTS: 
      Tinzaparin which is produced by the enzymatic depolymerization of unfractionated 
      heparin (UFH) can be used for the treatment and prevention of deep venous 
      thrombosis (DVT) and pulmonary embolism (PE); it has been also used in special 
      populations such as elders, obese, pregnant women, and patients with renal 
      impairment and/or cancer with favorable outcomes in both safety and efficacy, 
      with a once daily dose regimen. Furthermore, LMWHs are extensively used in 
      clinical practice for both thromboprophylaxis and thrombosis treatment of 
      COVID-19 patients. CONCLUSION: Tinzaparin features support the hypothesis for 
      having a role in immunothrombosis treatment (i.e. in the context of cancer 
      ,COVID-19), interfering not only with coagulation cascade but also exhibiting 
      anti-inflammatory potency.
CI  - (c) 2022. The Author(s).
FAU - Amerali, Marina
AU  - Amerali M
AD  - Hematology Laboratory-Blood Bank ARETAIEION Hospital, School of Medicine, 
      National and Kapodistrian University of Athens, Vasilissis Sofias 76, 11526, 
      Athens, Greece.
FAU - Politou, Marianna
AU  - Politou M
AD  - Hematology Laboratory-Blood Bank ARETAIEION Hospital, School of Medicine, 
      National and Kapodistrian University of Athens, Vasilissis Sofias 76, 11526, 
      Athens, Greece. mariannapolitou@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220723
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 7UQ7X4Y489 (Tinzaparin)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/therapeutic use
MH  - *COVID-19
MH  - Female
MH  - Heparin/therapeutic use
MH  - Heparin, Low-Molecular-Weight/pharmacology/therapeutic use
MH  - Humans
MH  - Pregnancy
MH  - *Thrombosis
MH  - Tinzaparin/therapeutic use
MH  - *Venous Thromboembolism/drug therapy
PMC - PMC9308487
OTO - NOTNLM
OT  - COVID-19
OT  - Elders
OT  - Heparin
OT  - Low molecular weight heparin
OT  - Obesity
OT  - Oncology
OT  - Thrombosis
OT  - Tinzaparin
COIS- The authors declare no competing interests. The authors declare no competing 
      interests.
EDAT- 2022/07/24 06:00
MHDA- 2022/09/21 06:00
PMCR- 2022/07/23
CRDT- 2022/07/23 23:55
PHST- 2022/04/03 00:00 [received]
PHST- 2022/07/16 00:00 [accepted]
PHST- 2022/07/24 06:00 [pubmed]
PHST- 2022/09/21 06:00 [medline]
PHST- 2022/07/23 23:55 [entrez]
PHST- 2022/07/23 00:00 [pmc-release]
AID - 10.1007/s00228-022-03365-4 [pii]
AID - 3365 [pii]
AID - 10.1007/s00228-022-03365-4 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 2022 Oct;78(10):1555-1565. doi: 10.1007/s00228-022-03365-4. 
      Epub 2022 Jul 23.